KEAP1 and lung cancer: In about 30% of human lung cancer cases, mutations arise in either KEAP1 or NRF2 (encoded by Nfe2l2), leading to NRF2 stabilizing and the modulation of oxidative homeostasis.[254] However, the accumulation of NRF2 in lung cancer induces HO‐1, an enzyme catalyzing heme degradation, leading to the stabilization of BACH1, which subsequently facilitates the metastasis of lung adenocarcinoma (LUAD).